文献速递哮喘

尿白三烯E4与前列腺素D2代谢物在2型炎症型成人及儿童重症哮喘中升高

Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

该临床观察研究基于U-BIOPRED队列,量化了86例轻中度哮喘、411例重症哮喘和100例健康对照的尿类花生酸代谢物,并在302例重症哮喘随访及95例青少年哮喘中验证。研究发现尿LTE4和PGD2代谢物高浓度与2型炎症标志物及肺功能下降相关,监测尿类花生酸可无创识别2型哮喘。

要点

  • 尿LTE4和PGD2代谢物升高与2型炎症标志物及较低肺功能相关。
  • 尿类花生酸代谢物检测对2型炎症的敏感性与现有生物标志物相当。
  • 监测尿类花生酸为成人和青少年哮喘分子分型提供无创新方法。

核心结论

  • 监测尿类花生酸可识别2型哮喘,为成人和青少年哮喘分子分型提供无创新方法。

研究设计与样本

  • U-BIOPRED临床观察研究,纳入86例轻中度哮喘、411例重症哮喘和100例健康对照。
  • 内部验证在302例重症哮喘患者12-18个月随访时进行,外部验证在95例青少年哮喘患者中进行。

主要发现

  • 健康对照尿代谢物浓度与年龄、BMI和性别无关,但PGE2通路除外。
  • 哮喘患者尿类花生酸浓度一般高于健康对照,重症哮喘进一步升高;但男性非吸烟哮喘患者PGE2代谢物浓度与健康对照相同或更低。
  • 经尿泼尼松龙检测确认坚持口服糖皮质激素治疗的哮喘患者代谢物浓度无变化;接受奥马珠单抗治疗的重症哮喘患者LTE4和PGD2代谢物2,3-dinor-11β-PGF2α浓度较低。
  • 高浓度LTE4和PGD2代谢物与较低肺功能及呼出气一氧化氮和血、痰、尿嗜酸性粒细胞标志物增加相关。
  • 这些2型哮喘关联在U-BIOPRED随访中重现,且对2型炎症的检测敏感性与现有生物标志物相当。

临床怎么用

  • 可考虑监测尿LTE4和PGD2代谢物作为无创手段辅助识别成人及青少年2型哮喘。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: New approaches are needed to guide personalized treatment of asthma.Objectives: To test if urinary eicosanoid metabolites can direct asthma phenotyping.Methods: Urinary metabolites of prostaglandins (PGs), cysteinyl leukotrienes (CysLTs), and isoprostanes were quantified in the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes) study including 86 adults with mild-to-moderate asthma (MMA), 411 with severe asthma (SA), and 100 healthy control participants. Validation was performed internally in 302 participants with SA followed up after 12-18 months and externally in 95 adolescents with asthma.Measurement and Main Results: Metabolite concentrations in healthy control participants were unrelated to age, body mass index, and sex, except for the PGE2 pathway. Eicosanoid concentrations were generally greater in participants with MMA relative to healthy control participants, with further elevations in participants with SA. However, PGE2 metabolite concentrations were either the same or lower in male nonsmokers with asthma than in healthy control participants. Metabolite concentrations were unchanged in those with asthma who adhered to oral corticosteroid treatment as documented by urinary prednisolone detection, whereas those with SA treated with omalizumab had lower concentrations of LTE4 and the PGD2 metabolite 2,3-dinor-11β-PGF2α. High concentrations of LTE4 and PGD2 metabolites were associated with lower lung function and increased amounts of exhaled nitric oxide and eosinophil markers in blood, sputum, and urine in U-BIOPRED participants and in adolescents with asthma. These type 2 (T2) asthma associations were reproduced in the follow-up visit of the U-BIOPRED study and were found to be as sensitive to detect T2 inflammation as the established biomarkers.Conclusions: Monitoring of urinary eicosanoids can identify T2 asthma and introduces a new noninvasive approach for molecular phenotyping of adult and adolescent asthma.Clinical trial registered with www.clinicaltrials.gov (NCT01976767).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Kolmert J, Gómez C, Balgoma D, et al. Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. Am J Respir Crit Care Med. 2021. PMID: 32667261. doi:10.1164/rccm.201909-1869OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。